<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083183</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005632</org_study_id>
    <secondary_id>NCI-2019-05727</secondary_id>
    <secondary_id>9524</secondary_id>
    <secondary_id>P01HL122173-01</secondary_id>
    <nct_id>NCT04083183</nct_id>
  </id_info>
  <brief_title>Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases</brief_title>
  <official_title>Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose of total body irradiation with astatine-211&#xD;
      BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases&#xD;
      undergoing hematopoietic cell transplant. Radiation therapy uses high energy gamma rays to&#xD;
      kill cancer cells and shrink tumors. Astatine-211-labeled BC8-B10 monoclonal antibody is a&#xD;
      monoclonal antibody, called anti-CD45 monoclonal antibody BC8-B10, linked to a&#xD;
      radioactive/toxic agent called astatine 211. Anti-CD45 monoclonal antibody BC8-B10 is&#xD;
      attached to CD45 antigen positive cancer cells in a targeted way and delivers astatine 211 to&#xD;
      kill them. Giving astatine-211 BC8-B10 monoclonal antibody and total-body irradiation before&#xD;
      a donor stem cell transplant may help stop the growth of cells in the bone marrow, including&#xD;
      normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's&#xD;
      immune system from rejecting the donor's stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 intravenously (IV) on&#xD;
      any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1&#xD;
      hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2.&#xD;
      Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5,&#xD;
      patients also receive mycophenolate mofetil orally (PO) or IV thrice daily every 8 hours up&#xD;
      to day 35 if no GVHD present and sirolimus PO daily until day 365.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 and 2 years and then&#xD;
      periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">January 9, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft rejection (arm A)</measure>
    <time_frame>Up to 5 years post-transplant</time_frame>
    <description>Defined as establishment of &lt; 5% donor chimerism of CD3+ T cells and &lt;5% donor chimerism of CD33+ myeloid cells at day 80-100 after hematopoietic cell transplant (HCT) following an human leukocyte antigen (HLA)-matched related or unrelated graft or an unrelated graft with a single HLA-class 1 allele mismatch or DQB1 antigen or allele mismatch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft rejection (arm B)</measure>
    <time_frame>Up to 5 years post-transplant</time_frame>
    <description>Defined as establishment of &lt; 5% donor chimerism of CD3+ T cells and &lt; 5% donor chimerism of CD33+ myeloid cells at day 80-100 after HCT following an HLA-haploidentical related donor or an unrelated donor mismatched for a single HLA-class 1 antigen or a single HLA-DRB1 allele.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute graft versus host disease (GVHD)</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic GVHD</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor chimerism</measure>
    <time_frame>At day 28, day 84, and 1 year post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10</other_name>
    <other_name>Astatine At 211 MAb BC8-B10</other_name>
    <other_name>At 211 Anti-CD45 Monoclonal Antibody BC8-B10</other_name>
    <other_name>At 211 MAb BC8-B10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>2-Fluorovidarabine</other_name>
    <other_name>21679-14-1</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoroadenine</other_name>
    <other_name>Fluradosa</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine, 21679-14-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lapine T-Lymphocyte Immune Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Anti-thymocyte Globulin Rabbit</other_name>
    <other_name>Grafalon</other_name>
    <other_name>Rabbit Anti-Human Thymocyte Globulin (RATG)</other_name>
    <other_name>Rabbit Anti-Thymocyte Globulin</other_name>
    <other_name>Rabbit Antithymocyte Globulin</other_name>
    <other_name>Rabbit ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>SCT_TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo hematopoietic cell transplantation</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
    <other_name>115007-34-6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nonmalignant disease treatable by allogeneic hematopoietic cell transplantation (HCT).&#xD;
             Patients with a nonmalignant disease that is not clearly defined must be approved by&#xD;
             the principal investigator (PI)&#xD;
&#xD;
          -  Lansky play performance score or Karnofsky score &gt;= 70&#xD;
&#xD;
          -  DONOR INCLUSION&#xD;
&#xD;
          -  HLA matched related donor that is genotypically or phenotypically identical for HLA-A,&#xD;
             -B, -C, -DRB1, -DQB1. Phenotypic identity must be confirmed by high-resolution typing.&#xD;
             Sibling donors are preferred over other relationships&#xD;
&#xD;
          -  Unrelated donor.&#xD;
&#xD;
               -  Matched for HLA-A, -B, -C, -DRB1, and DQB1 by high-resolution typing; OR&#xD;
&#xD;
               -  Mismatched for a single HLA-class 1 allele or HLA-DQB1 antigen or allele by&#xD;
                  high-resolution typing.&#xD;
&#xD;
        Note: A donor homozygous for one allele only at HLA-A, B, C, DRB1, or DQB1 is allowed (1&#xD;
        antigen mismatch for graft versus host disease [GVHD], 0 antigen mismatch for&#xD;
        graft-rejection). In the case of a recipient who is homozygous at one locus, the mismatch&#xD;
        is not allowed to be at that locus (0 antigen mismatch for GVHD, 1 antigen mismatch for&#xD;
        graft-rejection)&#xD;
&#xD;
          -  HLA haploidentical donor. There must be one shared HLA-haplotype based on inheritance.&#xD;
             The noninherited haplotype is allowed to be mismatched at any or all of these loci:&#xD;
             HLA-A, B, C, DRB1 or DQB1.&#xD;
&#xD;
          -  Donor selection guideline recommendations: in the case where there are multiple donor&#xD;
             options, donors should be selected based on the following priority numbered below:&#xD;
&#xD;
               -  Related donor genotypically HLA-matched&#xD;
&#xD;
               -  Related donor phenotypically HLA-matched&#xD;
&#xD;
               -  Unrelated donor HLA-matched&#xD;
&#xD;
               -  Unrelated donor with single allele level mismatch at class 1 (HLA-A, -B, or -C).&#xD;
                  For example, HLA-A02:01 versus HLA-A 02:02&#xD;
&#xD;
               -  Unrelated donor with single allele level mismatch at DQB1&#xD;
&#xD;
               -  HLA-haploidentical donor Note: We require that the donor testing be performed by&#xD;
                  a United States Clinical Laboratory Improvement Amendment (CLIA) approved&#xD;
                  laboratory. In the very rare case where the donor testing is not able to be&#xD;
                  performed in a CLIA approved laboratory, or there is confirmatory testing that&#xD;
                  needs to be performed, or for any donor identified from Europe and at risk for&#xD;
                  Creutzfeldt-Jakob Disease (CJD), we note this on the donor screening form and&#xD;
                  require that the unrelated donor medical director or the attending physician&#xD;
                  approves the use of the donor HPC-A product under urgent medical need&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Fanconi Anemia&#xD;
&#xD;
          -  Impaired cardiac function as evidenced by ejection fraction &lt; 35% (or, if unable to&#xD;
             obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac insufficiency&#xD;
             requiring treatment or symptomatic coronary artery disease. Patients with a shortening&#xD;
             fraction of &lt; 26% may be enrolled if approved by a cardiologist. In addition, patients&#xD;
             with poorly controlled hypertension on multiple anti-hypertensive medications,&#xD;
             symptomatic coronary artery disease, or patients on cardiac medications for&#xD;
             antiarrhythmic or inotropic effects are excluded&#xD;
&#xD;
          -  Impaired pulmonary function as evidenced by carbon monoxide diffusing capability test&#xD;
             (DLCO) &lt; 35% of predicted or receiving supplemental continuous oxygen. In addition, if&#xD;
             patients are unable to perform pulmonary function tests, then O2 saturation &lt; 92% on&#xD;
             room air&#xD;
&#xD;
          -  Impaired renal function as evidenced by estimated creatinine clearance less than 50&#xD;
             ml/min or serum creatinine &gt; 2 x upper normal limit or dialysis-dependent. Serum&#xD;
             creatinine value must be within 28 days prior to start of conditioning&#xD;
&#xD;
             * The creatinine clearance may be estimated by the Cockcroft-Gault formula&#xD;
&#xD;
          -  Impaired liver function as evidenced by abnormal hepatic function defined as a total&#xD;
             bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) &gt; 2&#xD;
             times the upper limit of normal. In addition, patients with the following liver&#xD;
             abnormalities are excluded: fulminant liver failure, cirrhosis of the liver with&#xD;
             evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic&#xD;
             encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by&#xD;
             prolongation of the prothrombin time, ascites related to portal hypertension,&#xD;
             bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or&#xD;
             symptomatic biliary disease&#xD;
&#xD;
          -  An uncontrolled infection requiring deferral of conditioning as recommended by an&#xD;
             infectious disease specialist. A viral upper respiratory tract infection does not&#xD;
             constitute an uncontrolled infection in this context&#xD;
&#xD;
          -  Patients who are known to be positive for HIV (human immunodeficiency virus)&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant or breast-feeding&#xD;
&#xD;
          -  Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment&#xD;
&#xD;
          -  Allergy to murine-based monoclonal antibodies&#xD;
&#xD;
          -  Known contraindication to radiotherapy&#xD;
&#xD;
          -  DONOR EXCLUSION&#xD;
&#xD;
          -  Donors are excluded when preexisting immunoreactivity is identified that would&#xD;
             jeopardize donor hematopoietic cell engraftment. The recommended procedure for&#xD;
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive&#xD;
             antibody (PRA) screens to class I and class II antigens for all patients before&#xD;
             hematopoietic cell transplantation (HCT). If the PRA shows &gt; 10% activity, then flow&#xD;
             cytometric or B and T cell cytotoxic cross matches should be obtained. The donor&#xD;
             should be excluded if any of the cytotoxic cross match assays are positive. For those&#xD;
             patients with an HLA class I allele or class II allele or antigen mismatch or&#xD;
             haploidentical donors, flow cytometric or B and T cell cytotoxic cross matches should&#xD;
             be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch&#xD;
             is an absolute donor exclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuong Vo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuong Vo</last_name>
    <phone>206-667-2749</phone>
    <email>ptvo@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Vo</last_name>
      <phone>206-667-2749</phone>
      <email>ptvo@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Phuong Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

